Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 451675, 10 pages
http://dx.doi.org/10.1155/2015/451675
Review Article

Mucocutaneous Involvement in Behçet’s Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives

1Interdisciplinary Department of Medicine, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
2Research Center of Systemic Autoimmune and Autoinflammatory Diseases, University of Siena, Viale Bracci 1, 53100 Siena, Italy
3Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126 Pisa, Italy

Received 12 April 2015; Accepted 19 May 2015

Academic Editor: Julio Galvez

Copyright © 2015 Cinzia Rotondo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Direskeneli, “Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?” Rheumatology, vol. 45, no. 12, pp. 1461–1465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. A. de Jesus and R. Goldbach-Mansky, “Monogenic autoinflammatory diseases: concept and clinical manifestations,” Clinical Immunology, vol. 147, no. 3, pp. 155–174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Muscari, F. Iacoponi, L. Cantarini et al., “The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature,” Autoimmunity Reviews, vol. 12, no. 1, pp. 10–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Hatemi, Y. Yazici, and H. Yazici, “Behçet's syndrome,” Rheumatic Disease Clinics of North America, vol. 39, no. 2, pp. 245–261, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Gül, “Behçet's disease as an autoinflammatory disorder,” Current Drug Targets: Inflammation and Allergy, vol. 4, no. 1, pp. 81–83, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Cantarini, G. Lopalco, F. Caso et al., “Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease,” Autoimmunity Reviews, vol. 14, no. 1, pp. 1–9, 2015. View at Publisher · View at Google Scholar
  7. G. Emmi, E. Silvestri, D. Squatrito et al., “Behçet's syndrome pathophysiology and potential therapeutic targets,” Internal and Emergency Medicine, vol. 9, no. 3, pp. 257–265, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Direskeneli, H. Fujita, and C. A. Akdis, “Regulation of TH17 and regulatory T cells in patients with Behçet disease,” Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 665–666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Mendoza-Pinto, M. García-Carrasco, M. Jiménez-Hernández et al., “Etiopathogenesis of Behcet's disease,” Autoimmunity Reviews, vol. 9, no. 4, pp. 241–245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Caso, L. Costa, D. Rigante et al., “Biological treatments in Behçet’s disease: beyond anti-TNF therapy,” Mediators of Inflammation, vol. 2014, Article ID 107421, 14 pages, 2014. View at Publisher · View at Google Scholar
  11. M. P. de Chambrun, B. Wechsler, G. Geri, P. Cacoub, and D. Saadoun, “New insights into the pathogenesis of Behçet's disease,” Autoimmunity Reviews, vol. 11, no. 10, pp. 687–698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Y. Zhou, S. L. Chen, N. Shen, and Y. Lu, “Cytokines and Behcet's disease,” Autoimmunity Reviews, vol. 11, no. 10, pp. 699–704, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Mege, N. Dilsen, V. Sanguedolce et al., “Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects,” Journal of Rheumatology, vol. 20, no. 9, pp. 1544–1549, 1993. View at Google Scholar · View at Scopus
  14. A. F. de Vos, M. A. C. van Haren, C. Verhagen, R. Hoekzema, and A. Kijlstra, “Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat,” Investigative Ophthalmology & Visual Science, vol. 35, no. 3, pp. 1100–1106, 1994. View at Google Scholar · View at Scopus
  15. S. Hirohata, H. Kikuchi, T. Sawada et al., “Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis,” Modern Rheumatology, vol. 22, no. 3, pp. 405–413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Hamzaoui, M. Hamza, and K. Ayed, “Production of TNF-α and IL-1 in active Behcet's disease,” The Journal of Rheumatology, vol. 17, no. 10, pp. 1428–1429, 1990. View at Google Scholar · View at Scopus
  17. S. Pay, H. Erdem, A. Pekel et al., “Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1β play a major role in Behçet's synovitis?” Rheumatology International, vol. 26, no. 7, pp. 608–613, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Mesquida, B. Molins, V. Llorenç et al., “Current and future treatments for Behçet's uveitis: road to remission,” International Ophthalmology, vol. 34, no. 2, pp. 365–381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Botsios, P. Sfriso, A. Furlan, L. Punzi, and C. A. Dinarello, “Resistant Behçet disease responsive to anakinra,” Annals of Internal Medicine, vol. 149, no. 4, pp. 284–286, 2008. View at Google Scholar · View at Scopus
  20. L. Cantarini, A. Vitale, P. Scalini et al., “Anakinra treatment in drug-resistant Behcet's disease: a case series,” Clinical Rheumatology, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Vitale, D. Rigante, F. Caso et al., “Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series,” Dermatology, vol. 228, no. 3, pp. 211–214, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Gül, I. Tugal-Tutkun, C. A. Dinarello et al., “Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 563–566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Cantarini, I. Tinazzi, P. Caramaschi, F. Bellisai, A. Brogna, and M. Galeazzi, “Safety and efficacy of etanercept in children with juvenile-onset Behçets disease,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 551–555, 2009. View at Google Scholar · View at Scopus
  24. R. Talarico, L. Cantarini, A. d’Ascanio et al., “Development of de novo major involvement during follow-up in Behçet’s syndrome,” Clinical Rheumatology, 2015. View at Publisher · View at Google Scholar
  25. K. Tascilar, M. Melikoglu, S. Ugurlu, N. Sut, E. Caglar, and H. Yazici, “Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course,” Rheumatology, vol. 53, no. 11, pp. 2018–2022, 2014. View at Publisher · View at Google Scholar
  26. G. Akman-Demir, P. Serdaroglu, and B. Tasçi, “Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients,” Brain, vol. 122, no. 11, pp. 2171–2181, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. M.-H. Houman, S. Bellakhal, T. B. Salem et al., “Characteristics of neurological manifestations of Behçet's disease: a retrospective monocentric study in Tunisia,” Clinical Neurology and Neurosurgery, vol. 115, no. 10, pp. 2015–2018, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Koné-Paut, M. Darce-Bello, F. Shahram et al., “Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet's disease: an international cohort study of 110 patients. One-year follow-up data,” Rheumatology, vol. 50, no. 1, pp. 184–188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Alpsoy, C. C. Zouboulis, and G. E. Ehrlich, “Mucocutaneous lesions of Behçet's disease,” Yonsei Medical Journal, vol. 48, no. 4, pp. 573–585, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. G. E. Ehrlich, “Behçet’s disease: an update,” Comprehensive Therapy, vol. 25, no. 4, pp. 216–220, 1999. View at Publisher · View at Google Scholar
  31. H. K. Chang and K. S. Cheon, “The clinical significance of a pathergy reaction in patients with Behçet's disease,” Journal of Korean Medical Science, vol. 17, no. 3, pp. 371–374, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Hatemi, A. Silman, D. Bang et al., “EULAR recommendations for the management of Behçet disease,” Annals of the Rheumatic Diseases, vol. 67, no. 12, pp. 1656–1662, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Hatemi, M. Melikoglu, R. Tunc et al., “Apremilast for the treatment of Behçet’s syndrome: a phase II randomized, placebo-controlled, double-blind study,” Arthritis & Rheumatism, vol. 65, no. 10, supplement, p. S322, 2013. View at Google Scholar
  34. H. Yazici, H. Pazarli, C. G. Barnes et al., “A controlled trial OF azathioprine in Behçet’s syndrome,” The New England Journal of Medicine, vol. 322, no. 5, pp. 281–285, 1990. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Aktulga, M. Altac, A. Muftuoglu et al., “A double blind study of colchicine in Behcet's disease,” Haematologica, vol. 65, no. 3, pp. 399–402, 1980. View at Google Scholar · View at Scopus
  36. S. Yurdakul, C. Mat, Y. Tuzun et al., “A double-blind trial of colchicine in Behçet's syndrome,” Arthritis and Rheumatism, vol. 44, no. 11, pp. 2686–2692, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Davatchi, B. S. Abdollahi, A. T. Banihashemi et al., “Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial,” Modern Rheumatology, vol. 19, no. 5, pp. 542–549, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Çalgüneri, I. Ertenli, S. Kiraz, M. Erman, and I. Çelik, “Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease,” Dermatology, vol. 192, no. 2, pp. 125–128, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. M. M. Al-Waiz, K. E. Sharquie, M. H. A-Qaissi, and R. K. Hayani, “Colchicine and benzathine penicillin in the treatment of Behçet disease: a case comparative study,” Dermatology Online Journal, vol. 11, no. 3, article 3, 2005. View at Google Scholar · View at Scopus
  40. M.-T. Labro, “Immunological effects of macrolides,” Current Opinion in Infectious Diseases, vol. 11, no. 6, pp. 681–688, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Isogai, S. Ohno, S. Kotake et al., “Chemiluminescence of neutrophils from patients with Behçet's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora,” Archives of Oral Biology, vol. 35, no. 1, pp. 43–48, 1990. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Mumcu, T. Ergun, Y. Elbir et al., “Clinical and immunological effects of azithromycin in Behçet's disease,” Journal of Oral Pathology and Medicine, vol. 34, no. 1, pp. 13–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Mumcu, N. Inanç, F. T. Özdemir et al., “Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behçet's disease,” International Journal of Dermatology, vol. 52, no. 12, pp. 1561–1566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Kaneko, N. Oyama, and A. Nishibu, “Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms,” Yonsei Medical Journal, vol. 38, no. 6, pp. 444–454, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Hamuryudan, C. Mat, S. Saip et al., “Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial,” Annals of Internal Medicine, vol. 128, no. 6, pp. 443–450, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. B. De Wazières, H. Gil, N. Magy, S. Berthier, D. A. Vuitton, and J. L. Dupond, “Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients,” La Revue de Médecine Interne, vol. 20, no. 7, pp. 567–570, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. J. M. M. Gardner-Medwin, N. J. Smith, and R. J. Powell, “Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy,” Annals of the Rheumatic Diseases, vol. 53, no. 12, pp. 828–832, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Saylan and I. Saltik, “Thalidomide in the treatment of Behcet's syndrome,” Archives of Dermatology, vol. 118, no. 8, p. 536, 1982. View at Publisher · View at Google Scholar · View at Scopus
  49. D. M. Hamza, “Treatment of Behçet’s disease with thalidomide,” Clinical Rheumatology, vol. 5, no. 3, pp. 365–371, 1986. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Masuda, A. Urayama, M. Kogure, A. Nakajima, K. Nakae, and G. Inaba, “Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease,” The Lancet, vol. 333, no. 8647, pp. 1093–1096, 1989. View at Publisher · View at Google Scholar
  51. S. Assaad-Khalil, “Low-dose cyclosporin in Behçet's disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Behçet's disease,” in Behçet's Disease: Basic and Clinical Aspects, pp. 603–612, CRC Press, Boca Raton, Fla, USA, 1991. View at Google Scholar
  52. O. Avci, N. Gurler, and A. T. Gunes, “Efficacy of cyclosporine on mucocutaneons manifestations of Behçet’s disease,” Journal of the American Academy of Dermatology, vol. 36, no. 5, pp. 796–797, 1997. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Lin and G. Liang, “Behçet disease: recommendation for clinical management of mucocutaneous lesions,” Journal of Clinical Rheumatology, vol. 12, no. 6, pp. 282–286, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. K. E. Sharquie, “Suppression of Behcet's disease with dapsone,” British Journal of Dermatology, vol. 110, no. 4, pp. 493–494, 1984. View at Publisher · View at Google Scholar · View at Scopus
  55. K. E. Sharquie, R. A. Najim, and A. R. Abu-Raghif, “Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study,” Journal of Dermatology, vol. 29, no. 5, pp. 267–279, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Matsuda, S. Ohno, S. Hirohata et al., “Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study,” Drugs in R and D, vol. 4, no. 1, pp. 19–28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Alpsoy, C. Durusoy, E. Yilmaz et al., “Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study,” Archives of Dermatology, vol. 138, no. 4, pp. 467–471, 2002. View at Google Scholar · View at Scopus
  58. A. Boyvat, C. Şişman-Solak, and A. Gürler, “Long-term effects of interferon alpha 2A treatment in Behcet's disease,” Dermatology, vol. 201, no. 1, pp. 40–43, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. J. D. O'Duffy, K. Calamia, S. Cohen et al., “Interferon-α treatment of Behcet's disease,” The Journal of Rheumatology, vol. 25, no. 10, pp. 1938–1944, 1998. View at Google Scholar · View at Scopus
  60. S. Georgiou, A. Monastirli, E. Pasmatzi, S. Gartaganis, G. Goerz, and D. Tsambaos, “Efficacy and safety of systemic recombinant interferon-alpha in Behçet’s disease,” Journal of Internal Medicine, vol. 243, no. 5, pp. 367–372, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Azizlerli, R. Sarica, A. Köse et al., “Interferon alfa-2a in the treatment of Behçet's disease,” Dermatology, vol. 192, no. 3, pp. 239–241, 1996. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Alpsoy, E. Yilmaz, and E. Basaran, “Interferon therapy for Behçet’s disease,” Journal of the American Academy of Dermatology, vol. 31, no. 4, pp. 617–619, 1994. View at Publisher · View at Google Scholar · View at Scopus
  63. V. Hamuryudan, F. Moral, S. Yurdakul et al., “Systemic interferon alpha 2b treatment in Behçet’s syndrome,” Journal of Rheumatology, vol. 21, no. 6, pp. 1098–1100, 1994. View at Google Scholar · View at Scopus
  64. C. Zouboulis, R. Treudler, and C. Orfanos, “Adamantiades-Behçet’s disease. Therapeutic administration of systemic recombinant interferon-α-2a,” Der Hautarzt, vol. 44, pp. 440–445, 1993. View at Google Scholar
  65. C. C. Zouboulis and C. E. Orfanos, “Treatment of Adamantiades-Behçet disease with systemic interferon alfa,” Archives of Dermatology, vol. 134, no. 8, pp. 1010–1016, 1998. View at Google Scholar · View at Scopus
  66. I. Kötter, I. Günaydin, M. Zierhut, and N. Stübiger, “The use of interferon α in Behçet disease: review of the literature,” Seminars in Arthritis and Rheumatism, vol. 33, no. 5, pp. 320–335, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Perez-Pampin, J. Campos-Franco, J. Blanco, and A. Mera, “Remission induction in a case of refractory behcet disease with alemtuzumab,” Journal of Clinical Rheumatology, vol. 19, no. 2, pp. 101–103, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. C. M. Lockwood, G. Hale, H. Waldman, and D. R. W. Jayne, “Remission induction in Behçet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H,” Rheumatology, vol. 42, no. 12, pp. 1539–1544, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. P. P. Sfikakis, “Behçet's disease: a new target for anti-tumour necrosis factor treatment,” Annals of the Rheumatic Diseases, vol. 61, no. 2, pp. ii51–ii53, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Sayinalp, O. I. Özcebe, O. Özdemir, I. C. Haznedaroglu, S. Dündar, and Ş. Kirazli, “Cytokines in Behçet's disease,” Journal of Rheumatology, vol. 23, no. 2, pp. 321–322, 1996. View at Google Scholar · View at Scopus
  71. G. Haugeberg, M. Velken, and V. Johnsen, “Successful treatment of genital ulcers with infliximab in Behçet's disease,” Annals of the Rheumatic Diseases, vol. 63, no. 6, pp. 744–745, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. B. Ordahan, A. Y. Karahan, S. C. Doğan, L. Tekin, S. Küçüksaraç, and E. Salbaş, “Infliximab treatment in co-existing behcet's disease and ankylosing spondylitis case presentation,” Journal of Rheumatology and Orthopedics, vol. 1, 2014. View at Publisher · View at Google Scholar
  73. I. Olivieri, L. Latanza, S. Siringo, G. Peruz, and V. Di Iorio, “Successful treatment of severe Behçet's disease with infliximab in an Italian olympic athlete,” The Journal of Rheumatology, vol. 35, no. 5, pp. 930–932, 2008. View at Google Scholar · View at Scopus
  74. I. Olivieri, A. Padula, P. Leccese, S. D'Angelo, and V. Giasi, “Long-lasting remission of severe Behçet's disease after the end of infliximab therapy,” Journal of Rheumatology, vol. 36, no. 4, article 855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Mohammed, “Etanercept therapy in Behçet’s disease,” Zeitschrift für Rheumatologie, vol. 73, no. 7, pp. 650–656, 2014. View at Publisher · View at Google Scholar
  76. M. Melikoglu, I. Fresko, C. Mat et al., “Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study,” Journal of Rheumatology, vol. 32, no. 1, pp. 98–105, 2005. View at Google Scholar · View at Scopus
  77. F. Atzeni, P. Sarzi-Puttini, F. Capsoni, M. Mecchia, M. G. Marrazza, and M. Carrabba, “Successful treatment of resistant Behçet's disease with etanercept,” Clinical and Experimental Rheumatology, vol. 23, no. 5, p. 729, 2005. View at Google Scholar · View at Scopus
  78. C. A. Dinarello, “Interleukin-1 in the pathogenesis and treatment of inflammatory diseases,” Blood, vol. 117, no. 14, pp. 3720–3732, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Bilginer, N. A. Ayaz, and S. Ozen, “Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease,” Clinical Rheumatology, vol. 29, no. 2, pp. 209–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Cantarini, A. Vitale, M. Borri, M. Galeazzi, and R. Franceschini, “Successful use of canakinumab in a patient with resistant Behçet's disease,” Clinical and Experimental Rheumatology, vol. 30, no. 3, supplement 72, p. S115, 2012. View at Google Scholar · View at Scopus